B cell lymphoma is a type of carcinoma that forms in immune B cells. This tumor may be either indolent (slow-growing) or aggressive (fast-growing). Majority of B cell lymphomas are non-Hodgkin lymphomas, which have evolved many different types, such as Burkitt lymphoma, chronic/small lymphocytic leukemia (CLL/SLL), mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. The monoclonal antibodies (Mabs) 32D1 and 31D1 were originally defined as anti-idiotypic as they identified an immunoglobulin (Ig) from the murine B cell lymphoma BCL1, but not other Igs of the same isotype as estimated by a radioimmunoassay (RIA). A promising artifact in determining anti-idiotypic antibodies by this means has possible to achieve copurification among antigen and antibody, leading to the recognization of anti-antigen as anti-idiotype. CD3 (Cluster of differentiation 3), originally known as T3, is one of the first groups of human T lymphocyte surface antigens recognized by monoclonal antibodies. It has been reported that antibodies against CD3 could either stimulate T cells to divide or inhibit the progress of effector functions according to the conditions used. It plays an important role in T cell and the CD3 T-cell co-receptor helps to activate the cytotoxic T-Cell and T helper cells. The CD3 molecule is composed of a protein complex and consists of four distinct chains. The complex of mammals contains a CD3γ chain, a CD3δ chain, and two CD3ε chains. All these chains associate with T-cell receptor and the ζ-chain to generate an activation signal in T lymphocytes.